- Q1 Revenue Reaches KRW 8.05 Billion, Driven by Expansion of Regenerative Medicine Platform in the U.S. and Beyond
- Company Focuses on Securing Future Growth Engines Through Strategic R&D Investment and Global Clinical Expansion
- Prioritizes Global Standard Leadership in AI-driven Hyper-Personalized Organ Regeneration Platform Over Short-Term Profitability

ROKIT Healthcare (KOSDAQ: 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, reported that its consolidated revenue for Q1 2026 more than doubled compared to the same period last year.

According to a regulatory disclosure filed by ROKIT Healthcare, the company recorded Q1 2026 revenue of KRW 8.05 billion — a 118% increase from KRW 3.69 billion in Q1 2025.

The revenue growth reflects a combination of expanded domestic and international business activities, strengthened responsiveness to overseas markets, and a more diversified revenue portfolio. The company continues to broaden its business presence in key markets including the United States and the Middle East, while advancing preparations to enhance the global commercialization potential of its AI-driven organ regeneration platform.

Operating loss for the quarter stood at approximately KRW 2.35 billion. This was primarily attributable to concentrated investment in future revenue-generating initiatives, including ▲global clinical expansion of the AI-driven cartilage regeneration platform, ▲domestic research on the AI-driven diabetic foot regeneration platform, ▲development of the AI-driven kidney predictive diagnostics platform, ▲global regulatory and licensing compliance efforts, and ▲advancement of the AI-based digital healthcare platform.

A ROKIT Healthcare representative stated, "Despite Q1 being a traditionally slow season in the industry, we achieved more than double the revenue growth compared to the same period last year, demonstrating the market viability of our platform," adding, "At this stage, establishing the global standard for AI-driven organ regeneration platforms and accumulating unrivaled clinical data is more critical to long-term enterprise value than short-term profit maximization."

The representative further noted, "Market entry into the United States, Saudi Arabia, and Latin America is proceeding as planned. This year, we are committed to further solidifying our position as the first mover in AI-driven organ regeneration platforms."